Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cardillo

Showing results (41-50 of 132) with videos related to

Pageof 14
Sort By:
Molecular Cancer Therapeutics|May 22, 2016
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric CancersChien-Hsing Chang, Yang Wang, Maria Zalath, et al.
Oncotarget|June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Oncotarget|March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Cancer Research|November 19, 2004
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancerDavid E Modrak, Thomas M Cardillo, Guy A Newsome, et al.
The British Journal of Dermatology|July 1, 1993
Transforming growth factor-beta distribution in basal cell carcinomas: relationship to proliferation indexG W Stamp, M Nasim, M Cardillo, et al.
Cancer Research|October 17, 2008
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeuticsEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Transplantation Proceedings|October 1, 1994
Factors influencing cadaver kidney graft survival in two cyclosporine periodsM Pappalettera, C Pizzi, M Cardillo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 3, 2012
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumabXiaochuan Chen, Chien-Hsing Chang, Rhona Stein, et al.
Transplantation Proceedings|March 27, 2001
A retrospective analysis of HLA matching and other factors on liver graft outcomeF Poli, S Frison, M Cardillo, et al.
Clinical Transplants|September 30, 1999
Cadaver kidney allocation in the north Italy transplant program on the eve of the new millenniumG Sirchia, F Poli, M Cardillo, et al.
Pageof 14

Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
Molecular Cancer Therapeutics|May 22, 2016
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric CancersChien-Hsing Chang, Yang Wang, Maria Zalath, et al.
Oncotarget|June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Oncotarget|March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Cancer Research|November 19, 2004
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancerDavid E Modrak, Thomas M Cardillo, Guy A Newsome, et al.
The British Journal of Dermatology|July 1, 1993
Transforming growth factor-beta distribution in basal cell carcinomas: relationship to proliferation indexG W Stamp, M Nasim, M Cardillo, et al.
Cancer Research|October 17, 2008
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeuticsEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Transplantation Proceedings|October 1, 1994
Factors influencing cadaver kidney graft survival in two cyclosporine periodsM Pappalettera, C Pizzi, M Cardillo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 3, 2012
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumabXiaochuan Chen, Chien-Hsing Chang, Rhona Stein, et al.
Transplantation Proceedings|March 27, 2001
A retrospective analysis of HLA matching and other factors on liver graft outcomeF Poli, S Frison, M Cardillo, et al.
Clinical Transplants|September 30, 1999
Cadaver kidney allocation in the north Italy transplant program on the eve of the new millenniumG Sirchia, F Poli, M Cardillo, et al.
Pageof 14